1Generini S, Matucci - Ceri,nic M. Raynaud' s phenomenon and vascular disease[J]. Adv Exp Med Biol. 1999,455:93 - 100.
2Turton EPL, Kent PJ, Kester RC. The aetiology of Raynaud's phenomenon [ J ]. Cardiovasc Surg. 1998,6:431 - 440.
3Levy Y,George J, Langevitz P,et al. Elevated homocysteine levels in patients with Raynaud' s syndrome[ J ]. J Rheumatol. 1999,26:2383 2385.
4Susol E, MacGregor AJ, Barrett JH, et al. A two - stage genome -wide screen for susceptibility loci ia primary Raynaud' s phenomenon [J]. Arthritis Rheum. 2000,43:1641 - 1646.
5Sedlacek K, Taub E. Biofeedback treatment of Raynaud's disease[ J]. Professional Psychology: Research and Practice. 1996,27(6) :548 -553.
6Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen - week, randomized, parallel - group, controlled trial [ J ]. Arihritis Rheum. 1999,42:2646 - 2655.
7Black CM, Halkier- Sфrensen L, Belch JJF, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre,placebo - controlled, dose - comparison study [ J ]. Br J Rheumatol.1998,37:952 - 960.
8Wigley FM,Kom JH,Csuka ME, et al. Oral ilopmst treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo - controlled, double - blind study [ J ]. Arthritis Rheum. 1998,41:670 -677.
9Lakshminarayanan S, Macstrello SJ, Vazquez -Abad D, et al. Treatment of severe Raynaud's phenomenon and ischemic ulceration with tissue plasminogen activator[ J ]. Clin Exp Rheumatol. 1999,17:260.
10Denton CP,Howell K,Stratton P,J,et al. Long- term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study[J]. Chin Exp Rheumatol. 2000 ,18 :499 -502.
